FOAMcast - An Emergency Medicine Podcast

Early studies of tocilizumab, a monoclonal antibody that binds interleukin-6 , were disappointing. However, the REMAP-CAP trial recently reported a benefit to tocilizumab in non-critically ill hospitalized patients with COVID-19. Now, from the RECOVERY trial (the trial that brought us dexamethasone), we have more good news for tocilizumab - which we cover in this podcast

Show notes: FOAMcast.org

Thanks for listening!
Lauren Westafer and Jeremy Faust

Direct download: recovery_toci_-_21321_9.45_AM.mp3
Category:general -- posted at: 9:48am EST